In Q4'25, ABBV's total revenue reached $17.7B USD, driven primarily by the Neuroscience segment at $5.2B USD, which marked its highest quarterly contribution, followed by Immunology at $8.7B USD, Oncology at $2.6B USD, and Aesthetics at $1.1B USD. This latest data point reflects a robust year-end performance, with Neuroscience showing significant growth from prior quarters. From Q1'23 to Q4'25, ABBV's revenue breakdown exhibits steady overall growth, with total quarterly revenues increasing from $5.6B USD to $17.7B USD, largely propelled by the dominant Immunology segment, which consistently accounted for 50-60% of totals and peaked at $9.0B USD in Q4'23. Neuroscience demonstrated the most volatile yet upward trajectory, surging from $0.7B USD in Q1'23 to $5.2B USD in Q4'25 with notable spikes in Q4'24 and Q3'25, while Oncology maintained stable mid-single-digit billion contributions, and Aesthetics fluctuated between $0.6B USD and $2.0B USD, often dipping in Q1 periods. This segment distribution highlights Immunology and Neuroscience as key growth drivers, underscoring ABBV's focus on high-margin therapeutic areas amid seasonal variations.